Full-Time

Vascular Clinical Specialist

Confirmed live in the last 24 hours

Penumbra Inc

Penumbra Inc

1,001-5,000 employees

Develops medical devices for vascular conditions

Biotechnology
Healthcare

Compensation Overview

$70k - $115kAnnually

+ Sales Incentive Program

Mid, Senior

No H1B Sponsorship

Raleigh, NC, USA

Candidates must reside within the Raleigh, NC region while in the role. Relocation expenditures will not be provided.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets

You match the following Penumbra Inc's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree in communications, neuroscience, biology or related discipline
  • Additional training and certification in radiology, neuro-interventional technology, or related field
  • 3+ years’ experience in a hospital setting or in a medical device company
  • Strong clinical, technical, and organizational skills
  • Ability to function in a busy, demanding, and competitive environment
  • Strong oral, verbal, written, and interpersonal communication skills
  • High degree of accuracy and attention to detail
  • Proficiency with MS Word, Excel, and PowerPoint
  • Excellent organizational skills with ability to prioritize assignments while handling various projects simultaneously
Responsibilities
  • Work with Regional Sales Manager and team members to develop and implement a regional plan aimed at increasing market share and improving quality of service to customers
  • Establish a system of communication with Regional Sales Manager and Territory Managers to ensure proper execution of plan and achievement of quarterly objectives
  • Develop relationships with hospital personnel to expand contacts in other departments, identify key decision makers and facilitate future sales
  • Meet with existing and potential customers to identify their clinical needs, goals and constraints related to patient care, and to demonstrate how Company products can help them achieve their goals
  • Educate existing and potential customers on the merits and proper clinical use of Company products by giving presentations and demonstrations
  • Keep customers abreast of the latest product, therapy, and technology developments, and current items of interest in the industry
  • Assist in professional education activities sponsored by Penumbra, including PEER meetings, hospital stroke symposia, and others
  • Assist in training new employees, including Territory Managers and Clinical Specialists
  • Participate in the development of Continuing Education Programs
  • Serve as primary resource for clinical support in the areas of procedural case coverage, basic troubleshooting, and follow-up for Company products
  • Report and track all product incidents at centers, following Company procedures and seeking input from appropriate personnel to resolve problems
  • Respond to customer needs and complaints by developing creative solutions, working in collaboration with senior management, sales, and marketing
  • Prospect and develop relationships with prospective customers and/or users of Penumbra products, converting them to Penumbra customers
  • Secure and/or renew existing orders by coordinating product availability, delivery dates, and inventory levels
  • Maintain open communication lines with current and prospective customers on programs, promotions, and pricing trends
  • Develop relationships with physicians, lab staff, lab supervisors, and purchasing personnel
  • Adhere to the Company’s Quality Management System (QMS) as well as domestic and global quality system regulations, standards, and procedures
  • Understand relevant security, privacy and compliance principles and adhere to the regulations, standards, and procedures that are applicable to the Company
  • Ensure other members of the department follow the QMS, regulations, standards, and procedures
  • Perform other work-related duties as assigned
Desired Qualifications
  • Sales or marketing background desired

Penumbra Inc. specializes in creating medical devices aimed at treating neurovascular and peripheral vascular conditions. Their products include a variety of devices for neuro interventions, such as the Penumbra System and the Penumbra SMART COIL, which are used to address issues like stroke. For peripheral vascular diseases, they offer the Indigo System and related devices. These products are designed to assist healthcare professionals in hospitals and clinics, primarily in Europe and the Americas. What sets Penumbra apart from competitors is their commitment to continuous research and development, ensuring their devices meet the changing needs of the medical field. The company's goal is to provide effective, high-quality medical solutions that improve patient outcomes in neurovascular and peripheral vascular care.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$116.7K

Headquarters

Alameda, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • The neurovascular devices market is projected to grow at a CAGR of 8.5% until 2030.
  • Penumbra's expansion in Costa Rica could reduce production costs and improve efficiency.
  • Technological advancements in clot retrieval devices enhance treatment outcomes for ischemic stroke.

What critics are saying

  • Don Kassing's retirement may lead to a gap in leadership and strategic guidance.
  • Operational challenges in Costa Rica could impact supply chain efficiency and product availability.
  • The Italian government's payback provision has already impacted financial results.

What makes Penumbra Inc unique

  • Penumbra offers a comprehensive range of neuro and peripheral vascular devices.
  • The company focuses on innovative solutions for stroke and neurovascular disease treatment.
  • Penumbra's global presence spans North and South America, Europe, Australia, and Asia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Feb 21st, 2025
Penumbra, Inc. Announces Don Kassing Will Retire From Board Of Directors

ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015."We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."Mr. Kassing is President Emeritus of San Jose State University

Investing.com
Feb 19th, 2025
UBS raises Penumbra stock price target to $320, keeps buy rating

Penumbra plans to expand its manufacturing capacity with a new facility in Costa Rica.

PR Newswire
Feb 18th, 2025
Penumbra, Inc. Reports Fourth Quarter And Full Year 2024 Financial Results

ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023. Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 13.4% in adjusted2 and adjusted constant currency2 compared to the full year 2023

PR Newswire
Jan 21st, 2025
Penumbra, Inc. Schedules Fourth Quarter And Full Year 2024 Earnings Release And Conference Call For February 18, 2025

ALAMEDA, Calif., Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. A press release with fourth quarter and full year 2024 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity

Interventional News
Jan 10th, 2025
Interventional News' top 10 most popular stories of 2024

The Society of Interventional Radiology (SIR) Foundation, The VIVA Foundation and Penumbra, today announced the launch of the EMBOLIZE trial, a first-of-its-kind prospective, randomised controlled trial studying the effects of ovarian vein embolization (OVE) and pelvic vein embolization in reducing pain in women experiencing chronic pelvic pain due to pelvic venous disease (PeVD).